Intellia Therapeutics
NTLA
292 hedge funds and large institutions have $2.68B invested in Intellia Therapeutics in 2023 Q4 according to their latest regulatory filings, with 48 funds opening new positions, 123 increasing their positions, 77 reducing their positions, and 36 closing their positions.
60% more repeat investments, than reductions
Existing positions increased: 123 | Existing positions reduced: 77
33% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 36
7.48% more ownership
Funds ownership: 90.55% → 98.03% (+7.5%)
6% more capital invested
Capital invested by funds: $2.53B → $2.68B (+$142M)
3% more funds holding
Funds holding: 284 → 292 (+8)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
30% less call options, than puts
Call options by funds: $21.1M | Put options by funds: $30.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$57.5M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$42.1M |
| 3 |
State Street
Boston,
Massachusetts
|
+$28.8M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$25.6M |
| 5 |
BlackRock
New York
|
+$25.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$20.4M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$8.81M |
| 3 |
AG
Artal Group
Luxembourg
|
-$8.73M |
| 4 |
Millennium Management
New York
|
-$7.37M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$6.21M |
NTLA Hedge Fund Activity: Q4 2023 in Review
292 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Intellia Therapeutics (NTLA) for Q4 2023, worth a combined $2.68B — up 5.6% from $2.53B a quarter earlier.
Buyers outnumbered sellers: 48 funds opened new NTLA positions and 36 closed out — a net gain of 12 holders — while 123 added to existing stakes and 77 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $57.5M. The largest seller was Citadel Advisors, cutting an estimated $20.4M.
- 292 institutional investors held Intellia Therapeutics (NTLA) as of Q4 2023, up from 284 in Q3 2023.
- Funds reported $2.68B of Intellia Therapeutics stock for Q4 2023, up 5.6% quarter-over-quarter.
- 48 funds opened new Intellia Therapeutics positions in Q4 2023 and 36 closed out, a net change of +12 holders.
- The largest Intellia Therapeutics buyer in Q4 2023 was Morgan Stanley, an estimated $57.5M added.
- The largest Intellia Therapeutics seller in Q4 2023 was Citadel Advisors, an estimated $20.4M sold.
Based on aggregated 13F filings for Q4 2023.